查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1880596

氨基糖苷类抗生素市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Aminoglycosides Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

氨基糖苷类抗生素市场成长驱动因子

受细菌感染病例增加、抗生素技术进步以及对治疗复杂呼吸道和泌尿道感染的有效疗法的需求不断增长的推动，全球氨基糖苷类抗生素市场持续稳步增长。根据最新的产业报告，预计到 2024 年，市场规模将达到 18.7 亿美元，2025 年将达到 19.2 亿美元，到 2032 年将达到 23.5 亿美元，复合年增长率 (CAGR) 为 2.95%。 2024 年，北美市场占主导地位，市场占有率为 41.17%，这得益于其完善的医疗保健体系、强有力的抗生素管理计划以及在重症病例管理中对氨基糖苷类抗生素的高采用率。

氨基糖苷类抗生素，如庆大霉素、妥布霉素、阿米卡星、链霉素和新霉素，是治疗严重感染的重要杀菌抗生素。它们独特的抗菌机制，即与细菌30S核醣体亚基结合并抑制蛋白质合成，使其对革兰氏阴性菌特别有效。与β-内酰胺类抗生素合併使用，进一步提升了其在加护病房（ICU）中的价值。吸入製剂和半合成衍生物等技术创新，提高了其安全性、给药途径和疗效。诸如史丹佛大学2022年旨在开发降低听力损失风险的氨基糖苷类药物的研究等研发工作，持续提升其市场潜力。

市场动态

市场推动因素

推动市场扩张的关键因素是全球泌尿道感染 (UTI) 病例的增加。人口老化、糖尿病患者增加、生活方式改变以及医院感染等因素正在加速对抗生素的需求。为了因应这些趋势，各公司正在扩展产品线并推出新的解决方案。 2024 年，Cipla 公司获得了印度中央药品监管和监督组织 (CDSCO) 的批准，可在印度销售其新一代氨基糖苷类抗生素普拉佐米星，用于治疗复杂性尿路感染，这反映出该公司加大了商业投资。

市场限制因子

日益严重的全球抗菌素抗药性 (AMR) 威胁对市场成长构成重大障碍。大肠桿菌、肺炎克雷伯菌和绿脓桿菌等病原体的抗药性正在迅速增强。 2023年，美国疾病管制与预防中心（CDC）报告称，美国医院中氨基糖苷类抗药性革兰氏阴性菌感染病例呈上升趋势；2024年，欧洲疾病预防控制中心（ECDC）指出，欧洲部分地区肺炎克雷伯菌血流感染的抗药性率超过25%。这些趋势对氨基糖苷类抗生素的长期疗效和应用构成了挑战。

市场机会

儘管存在抗药性问题，胜肽连接的氨基糖苷类缀合物为恢復现有药物对多重抗药性细菌的疗效提供了一个有前景的机会。 2025年发表在 "微生物学前沿" （Frontiers in Microbiology）上的一项研究证实了肽-新霉素缀合物与多粘菌素B之间存在显着的协同作用，表明修饰的氨基糖苷类药物具有克服酶促药物失活的潜力。

市场挑战

主要挑战在于耳毒性和肾毒性的风险，尤其是在携带罕见粒线体突变的个体中。即使在治疗范围内使用，氨基糖苷类抗生素也可能导致不可逆的听力损失。英国政府在2021年发布的关于治疗窗较窄的警告反映了持续存在的安全隐患，这可能会限制其更广泛的临床应用。

区隔市场亮点

依代划分

第三代氨基糖苷类抗生素在2024年引领市场，这得益于感染率的上升和其高疗效。策略性授权协议，例如Sifan Pharmaceutical于2022年达成的贝那培南和普拉佐米星的共同开发协议，巩固了该区隔市场的领先地位。

依应用领域

2024年，由于多重抗药性铜绿假单胞菌病例的增加以及囊性纤维化盛行率的上升，呼吸道感染成为市场主导领域。美国疾病管制与预防中心 (CDC) 报告称，美国有35,000人患有囊性纤维化，这推动了对先进吸入型氨基糖苷类药物的需求。

依给药途径

由于其局部活性和较低的全身风险，外用製剂在2024年占市场主导地位。 2024年，Appili Therapeutics公司推进了其用于治疗皮肤利甚曼病的局部用巴龙霉素製剂ATI-1801的研发。

依通路划分

2024年，零售药局在全球市场占主导地位，这主要得益于其便利性的提升和患者的高度信任。 Pharmaprix 2024年的诊所扩张计画也反映了零售通路抗生素销售的成长。

区域展望

北美仍是最大的区域市场，2024年销售额达7.7亿美元，主要得益于其完善的医疗保健系统和强大的抗生素研发能力。预计到2025年，欧洲市场将达到4.9亿美元，主要得益于抗菌药物管理和监管的加强。亚太地区预计到2025年将达到3.2亿美元，主要得益于传染病负担的加重和医药基础设施的持续改善。预计2025年，拉丁美洲市场将达到2亿美元，新兴市场预计将保持温和成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要疾病概述（依主要国家/地区划分，2024 年）
  • 主要国家的监管状况（2024 年）
  • 主要公司研发管线分析
  • 抗生素治疗指引摘要
  • 世卫组织抗生素抗药性 "优先病原体" 概要
  • 主要产业趋势：併购，收购、合作等

第五章：全球氨基糖苷类抗生素市场分析、洞察与预测（2019-2032 年）

  • 市场分析、洞察与预测 - 依世代划分
    • 第一代
    • 第二代
    • 第三代
    • 其他
  • 市场分析、洞察与预测 - 依应用划分
    • 泌尿道感染
    • 呼吸道感染
    • 皮肤感染
    • 眼部感染
    • 其他
  • 市场分析、洞察与预测 - 依给药途径划分
    • 口服
    • 肠外给药
    • 其他
  • 市场分析、洞察与预测 - 依销售额分割管道
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美氨基糖苷类抗生素市场分析、洞察与预测，2019-2032

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲氨基糖苷类抗生素市场分析、洞察与预测，2019-2032

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区氨基糖苷类抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲氨基糖苷类抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

章节10：中东和非洲氨基糖苷类抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
  • Amneal Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Insmed Incorporated
  • Pfizer Inc.
  • Cipla
  • Nordic Group B.V.
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
Product Code: FBI113880

Growth Factors of aminoglycosides Market

The global aminoglycosides market continues to grow steadily, driven by rising bacterial infections, advancements in antibiotic technologies, and increasing demand for effective treatments for complicated respiratory and urinary tract infections. According to the latest industry report, the market size was USD 1.87 billion in 2024, projected to rise to USD 1.92 billion in 2025, and expected to reach USD 2.35 billion by 2032, expanding at a CAGR of 2.95%. In 2024, North America led the market with a 41.17% share, supported by robust healthcare systems, strong antibiotic stewardship programs, and higher adoption of aminoglycosides for critical care management.

Aminoglycosides-such as gentamicin, tobramycin, amikacin, streptomycin, and neomycin-remain essential bactericidal antibiotics used in treating severe infections. Their unique mechanism of binding to the bacterial 30S ribosomal subunit disrupts protein synthesis, making them especially effective against gram-negative pathogens. Their synergy with B-lactam antibiotics further strengthens their use in intensive care units. Technological innovations, including inhaled formulations and semi-synthetic derivatives, are enhancing safety, delivery, and therapeutic efficiency. Research activities, such as Stanford University's 2022 study aiming to develop hearing-loss-safe aminoglycosides, continue to elevate market potential.

Market Dynamics

Market Drivers

A key driver contributing to market uptake is the rising global prevalence of urinary tract infections (UTIs). Factors such as population aging, increasing diabetes incidence, lifestyle changes, and hospital-acquired infections have accelerated antibiotic demand. Responding to these trends, companies are expanding portfolios and introducing new solutions. In 2024, Cipla received approval from CDSCO to market Plazomicin, a next-generation aminoglycoside for complicated UTIs in India, reflecting growing commercial investments.

Market Restraints

The increasing global threat of antimicrobial resistance (AMR) poses a substantial barrier to market growth. Resistance in pathogens such as E. coli, K. pneumoniae, and P. aeruginosa is rising sharply. CDC reported in 2023 that aminoglycoside-resistant gram-negative infections are spreading across U.S. hospitals, while ECDC noted in 2024 that resistance in K. pneumoniae bloodstream infections exceeded 25% in parts of Europe. These trends challenge the long-term efficacy and adoption of aminoglycosides.

Market Opportunities

Despite resistance concerns, a promising opportunity lies in peptide-linked aminoglycoside conjugates, which restore the effectiveness of existing drugs against MDR organisms. A 2025 Frontiers in Microbiology study revealed strong synergistic action between peptide-neomycin conjugates and polymyxin B, highlighting the potential of modified aminoglycosides to overcome enzymatic drug inactivation.

Market Challenges

A major challenge is the risk of ototoxicity and nephrotoxicity, especially for individuals with rare mitochondrial mutations. Even when dosed within therapeutic ranges, aminoglycosides can cause irreversible hearing loss. The U.K. government's 2021 warning about narrow therapeutic windows reflects ongoing safety concerns that may limit broader clinical adoption.

Segmentation Highlights

By Generation

The third-generation aminoglycosides segment dominated in 2024, supported by increasing infection rates and high efficacy. Strategic licensing agreements-such as Sihuan Pharmaceutical's 2022 collaboration for Benapenem and Plazomicin-reinforce segment leadership.

By Application

In 2024, respiratory tract infections led the market due to rising MDR-Pseudomonas cases and growing cystic fibrosis prevalence. The CDC reported 35,000 people living with CF in the U.S., driving demand for advanced inhaled aminoglycosides.

By Route of Administration

The topical segment dominated in 2024 owing to localized action and lower systemic risk. In 2024, Appili Therapeutics advanced ATI-1801, a topical paromomycin formulation for cutaneous leishmaniasis.

By Distribution Channel

Retail pharmacies led the global market in 2024, driven by improved accessibility and high trust levels among patients. Pharmaprix's 2024 clinic expansion reflects growth in retail-based antibiotic dispensing.

Regional Outlook

North America remained the largest regional market in 2024 with revenues of USD 0.77 billion, backed by established healthcare systems and strong antibiotic R&D. Europe is forecast to reach USD 0.49 billion in 2025, supported by antimicrobial stewardship and regulatory oversight. Asia Pacific is projected to attain USD 0.32 billion in 2025, driven by rising infectious disease burdens and expanding pharmaceutical infrastructure. Latin America is expected to reach USD 0.20 billion in 2025, with moderate growth across emerging markets.

Conclusion

With the market projected to grow from USD 1.87 billion in 2024 to USD 2.35 billion by 2032, the aminoglycosides sector continues to evolve through product innovation, combination therapy expansion, and advanced antibiotic development. Despite AMR and toxicity challenges, sustained R&D and improved drug formulations are expected to support stable long-term market growth.

Segmentation By Generation

  • First Generation
  • Second Generation
  • Third Generation
  • Others

By Application

  • Urinary Tract Infections
  • Respiratory Tract Infection
  • Skin Infections
  • Ophthalmic Infections
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (By Generation, Application, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Key Diseases, By Key Countries/ Region, 2024
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2024
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview of Antimicrobial Treatment Guidelines
  • 4.5. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
  • 4.6. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Urinary Tract Infections
    • 5.2.2. Respiratory Tract Infection
    • 5.2.3. Skin Infections
    • 5.2.4. Opthalmic Infections
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Urinary Tract Infections
    • 6.2.2. Respiratory Tract Infection
    • 6.2.3. Skin Infections
    • 6.2.4. Opthalmic Infections
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Urinary Tract Infections
    • 7.2.2. Respiratory Tract Infection
    • 7.2.3. Skin Infections
    • 7.2.4. Opthalmic Infections
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Urinary Tract Infections
    • 8.2.2. Respiratory Tract Infection
    • 8.2.3. Skin Infections
    • 8.2.4. Opthalmic Infections
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Urinary Tract Infections
    • 9.2.2. Respiratory Tract Infection
    • 9.2.3. Skin Infections
    • 9.2.4. Opthalmic Infections
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Urinary Tract Infections
    • 10.2.2. Respiratory Tract Infection
    • 10.2.3. Skin Infections
    • 10.2.4. Opthalmic Infections
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
    • 11.2.1. Amneal Pharmaceuticals, Inc.
    • 11.2.2. Hikma Pharmaceuticals PLC
    • 11.2.3. Insmed Incorporated
    • 11.2.4. Pfizer Inc.
    • 11.2.5. Cipla
    • 11.2.6. Nordic Group B.V.
    • 11.2.7. Lupin
    • 11.2.8. Sun Pharmaceutical Industries Ltd.
    • 11.2.9. Dr. Reddy's Laboratories Ltd.

List of Tables

  • Table 1: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 2: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 3: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 4: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 7: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Aminoglycosides Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 12: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 13: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 14: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 17: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 18: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 19: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 22: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 23: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 24: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
  • Table 27: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 28: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 29: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Aminoglycosides Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Aminoglycosides Market Value Share (%), by Generation, 2024 & 2032
  • Figure 3: Global Aminoglycosides Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Aminoglycosides Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 5: Global Aminoglycosides Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Aminoglycosides Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 8: North America Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 9: North America Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 10: North America Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 11: North America Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 12: North America Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 13: North America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Aminoglycosides Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Aminoglycosides Market Value Share (%), By Country, 2024
  • Figure 17: Europe Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 18: Europe Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 19: Europe Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 20: Europe Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 21: Europe Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 22: Europe Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 23: Europe Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 28: Asia Pacific Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 29: Asia Pacific Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 30: Asia Pacific Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 31: Asia Pacific Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 32: Asia Pacific Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 33: Asia Pacific Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 38: Latin America Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 39: Latin America Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 40: Latin America Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 41: Latin America Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 42: Latin America Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 43: Latin America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
  • Figure 48: Middle East & Africa Aminoglycosides Market Value Share (%), by Generation, 2024
  • Figure 49: Middle East & Africa Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
  • Figure 50: Middle East & Africa Aminoglycosides Market Value Share (%), by Application, 2024
  • Figure 51: Middle East & Africa Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 52: Middle East & Africa Aminoglycosides Market Value Share (%), by Route of Administration, 2024
  • Figure 53: Middle East & Africa Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Aminoglycosides Market Share (%), By Company, 2024